Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 Bristol-Myers Squibb Co at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021 / 05:00PM GMT
Release Date Price:
$67.2
(+0.24%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
This is Navin Jacob, welcome to the UBS Global Healthcare Conference. Our next session is with Bristol-Myers Squibb. As I said, my name is Navin Jacob. I cover large-cap pharma and Biotech. Thanks for being with us. And from Bristol, we have Samit Hirawat, EVP and Chief Medical Officer; as well as David Elkins, EVP and Chief Financial Officer. Thank you, gentlemen, for joining us today.
David V. Elkins
Bristol-Myers Squibb Company - Executive VP & CFO
Great, Navin.
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
So what we're going to do this afternoon is have a fireside session with the folks from Bristol, which will be driven by me. But folks online, you are able to actually ask questions over the internet. At the bottom of your screen, you should be able to submit those
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot